<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s2{background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s4{background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s0{background-color:#ffffff;text-align:left;font-weight:bold;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{background-color:#ffffff;text-align:left;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s5{background-color:#ffffff;text-align:left;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="1063773919C0" style="width:909px;" class="column-headers-background">A</th></tr></thead><tbody><tr style="height: 20px"><th id="1063773919R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0" dir="ltr">Major Obstetric Haemorrhage</td></tr><tr style="height: 20px"><th id="1063773919R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td class="s1"></td></tr><tr style="height: 20px"><th id="1063773919R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s2" dir="ltr">Red blood cell transfusion</td></tr><tr style="height: 20px"><th id="1063773919R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s1" dir="ltr">There are no firm criteria for initiating red cell transfusion.</td></tr><tr style="height: 20px"><th id="1063773919R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s3" dir="ltr">The decision to provide blood transfusion should be made on clinical and haematological grounds. </td></tr><tr style="height: 20px"><th id="1063773919R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s3" dir="ltr">In an extreme situation and when the blood group is unknown, group O RhD-negative red cells should be given (although they may be incompatible for patients with irregular antibodies). </td></tr><tr style="height: 20px"><th id="1063773919R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s3" dir="ltr">Staff working in obstetric units should be aware of the location of the satellite blood fridge (where available) and should ensure that access is possible for blood collection. </td></tr><tr style="height: 20px"><th id="1063773919R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s1"></td></tr><tr style="height: 20px"><th id="1063773919R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s4" dir="ltr">FFP</td></tr><tr style="height: 20px"><th id="1063773919R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s3" dir="ltr">FFP at a dose of 12â€“15 ml/kg should be administered for every 6 units of red cells during major obstetric haemorrhage. </td></tr><tr style="height: 20px"><th id="1063773919R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s3" dir="ltr">Subsequent FFP transfusion should be guided by the results of clotting tests if they are available in a timely manner, aiming to maintain prothrombin time (PT) and activated partial thromboplastin time (APTT) ratios at less than 1.5 x normal.</td></tr><tr style="height: 20px"><th id="1063773919R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s3" dir="ltr">It is essential that regular full blood counts and coagulation screens (PT, APTT and fibrinogen) are performed during the bleeding episode. </td></tr><tr style="height: 20px"><th id="1063773919R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s3" dir="ltr"></td></tr><tr style="height: 20px"><th id="1063773919R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s4" dir="ltr">Cryo</td></tr><tr style="height: 20px"><th id="1063773919R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s3" dir="ltr">Cryoprecipitate at a standard dose of two 5-unit pools should be administered early in major obstetric haemorrhage. </td></tr><tr style="height: 20px"><th id="1063773919R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s3" dir="ltr">Subsequent cryoprecipitate transfusion should be guided by fibrinogen results, aiming to keep levels above 1.5 g/l. </td></tr><tr style="height: 20px"><th id="1063773919R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td class="s3" dir="ltr">The FFP and cryoprecipitate should ideally be of the same group as the recipient. </td></tr><tr style="height: 20px"><th id="1063773919R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s3" dir="ltr">If unavailable, FFP of a different ABO group is acceptable providing that it does not have a high titre of anti-A or anti-B activity. </td></tr><tr style="height: 20px"><th id="1063773919R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s1"></td></tr><tr style="height: 20px"><th id="1063773919R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s1" dir="ltr">NB: No anti-D prophylaxis is required if a RhD-negative woman receives RhD-positive FFP or cryoprecipitate.</td></tr><tr style="height: 20px"><th id="1063773919R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s1"></td></tr><tr style="height: 20px"><th id="1063773919R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s2" dir="ltr">Cell Salvage</td></tr><tr style="height: 20px"><th id="1063773919R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s1" dir="ltr">Cell salvage is recommended for patients where the anticipated blood loss is great enough to induce anaemia or expected to exceed 20% of estimated blood volume. </td></tr><tr style="height: 20px"><th id="1063773919R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s3" dir="ltr">Where IOCS is used during caesarean section in RhD-negative, previously nonsensitised women and where cord blood group is confirmed as RhD positive (or unknown), a minimum dose of 1500 iu anti-D immunoglobulin should be administered following the reinfusion of salvaged red cells.</td></tr><tr style="height: 20px"><th id="1063773919R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s1"></td></tr><tr style="height: 20px"><th id="1063773919R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s2" dir="ltr">Platelets</td></tr><tr style="height: 20px"><th id="1063773919R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">27</div></th><td class="s1" dir="ltr">Aim to maintain the platelet count above 50 x 109/l in the acutely bleeding patient.</td></tr><tr style="height: 20px"><th id="1063773919R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">28</div></th><td class="s5" dir="ltr">A platelet transfusion trigger of 75 x 10^9/l is recommended to provide a margin of safety. </td></tr><tr style="height: 20px"><th id="1063773919R28" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">29</div></th><td class="s5" dir="ltr">The platelets should ideally be group compatible. RhD-negative women should also receive RhDnegative platelets.</td></tr></tbody></table></div>